Hard-hitting CLL news coming your way soon! @OncLive @mshadman

Pirtobrutinib is now approved for pts with #CLL after cBTKi. Pirtobrutinib can now be used in second line, potentially. Big #ASH25 for pirtobrutinib! https://t.co/IBjAEJaQNV

Patient focus Many pts who could benefit from #CART are never referred — often because they’re unaware it’s an option. I recorded a short video with @fredhutch to help pts and families understand why early referral matters. https://t.co/v2cUJ0qZtI

Congrats @ekimblepl et. al.

Bruin 313 (LBA #ASH25): Pirtobrutinib vs. BR in TN #CLL. With 28 m Fu: PFS HR 0.18 and OS HR 0.28 (!) in favor of pirto. Very interesting and can't wait to see the details! Will have a busy ASH and post ASH!

Am I confused or #ASH25 has changed the schedule format on their website?

Our lead Dr. @mana1981 is senior author of a study in @ASTCT showing 95-97% of CRS/ICANS events occur before day 15 after liso-cel infusion in the real-world setting. These results led to the recent FDA REMS changes for post-CAR monitoring. #lymsm #tcellrx https://t.co/zj0tyIqvZe

#ASH25 Excited to present the longer follow-up of Zanubrutinib and Venetoclax for 1L #CLL (SEQUOIA arm D) https://t.co/9oef6udZNn @fredhutch

#ASH25 presentation: Will report on 48 pts with #CLL who were retreated with #venetoclax https://t.co/15NbM1AHCW @fredhutch @abbvie

#ASH25 Trial in progress (@fredhutch IIT) SONIC: ultra-rapid dose escalation of Sonrotoclax in #CLL and #MCL https://t.co/by7kQspEXK @DrJenniferHuang @LauraSamplesMD

#ASH25 presentation: Will present this important data using the @KomodoHealth US claims database confirming that ~80% of patients with #LBCL with 2L+ txs don't receive #CART due to barriers like limited referrals. https://t.co/n9mkapIOEX @fredhutch @bmsnews

#ASH25 oral presentation: Dr. @DrJenniferHuang will present the RWE of #CART for #CLL with liso-cel: https://t.co/xyLUNla24u Another great collaboration with our amazing CLL academic community! @fredhutch

https://t.co/YQBJpDsOuo

We just published our commentary in Blood (@BloodPortfolio) 🩸 on real-world CD20 bispecifics in DLBCL. https://t.co/xDRUcnnL9e Key takeaways: • Outcomes appear shorter than trials • CD20 loss is a key resistance mechanism @fredhutch

Fantastic news: congrats to rising star @RubenRaychaud mentored by brilliant colleagues Mike Schweizer, Pete Nelson, Michael Haffner for @PCFnews YIA on his work on epigenetic modulation of PSMA expression & response to LuPSMA! Proud of our @fredhutch @uwurology team! @DanLinMD

Congrats to my amazing colleagues @SteveBlinka @MikeSchweizerMD for getting @PCFnews / foundation medicine collaboration award! They work hard along with @HsiehLab & our stellar team @fredhutch @uwurology to move #prostatecancer field forward! @spsutkaMD @DanLinMD @neerajaiims

There’s still much work ahead to expand access and make this life-saving therapy more feasible—but “medical unfitness” should never be assumed. 3/3 #CART @fredhutch @ASTCT @lymphoma @lymphomahub @Cure_FL @LysaLymphoma @TheEBMT @CIBMTR

While some patients may be truly ineligible, they represent a small minority. Most can safely receive—or be optimized for—CAR-T therapy with appropriate medical management. 2/3

Every patient with relapsed lymphoma deserves an official consultation with a CAR-T expert. CAR-T cell therapy has been associated with improved overall survival in DLBCL, and longer follow-up now suggests the potential for cure in both aggressive and indolent lymphomas. 1/3

We just published our paper comparing eligibility criteria for #CAR-T vs autoSCT. They are NOT the same! Key message: Most patients are eligible for CAR-T, even with significant comorbidities. Collaboration with other specialists is key to optimizing patients clinical situation.